CN116802180A - 一种降解脱氧核糖核酸(dna)聚合酶的化合物及其用途 - Google Patents
一种降解脱氧核糖核酸(dna)聚合酶的化合物及其用途 Download PDFInfo
- Publication number
- CN116802180A CN116802180A CN202280011048.5A CN202280011048A CN116802180A CN 116802180 A CN116802180 A CN 116802180A CN 202280011048 A CN202280011048 A CN 202280011048A CN 116802180 A CN116802180 A CN 116802180A
- Authority
- CN
- China
- Prior art keywords
- optionally
- compound
- polymerase
- dna
- lgp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 119
- 108020004414 DNA Proteins 0.000 title claims abstract description 62
- 102000053602 DNA Human genes 0.000 title claims abstract description 62
- 230000000593 degrading effect Effects 0.000 title abstract description 10
- 241000700605 Viruses Species 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 22
- 239000003446 ligand Substances 0.000 claims abstract description 21
- 230000003612 virological effect Effects 0.000 claims abstract description 20
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims abstract description 12
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims abstract description 12
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 7
- 208000037921 secondary disease Diseases 0.000 claims abstract description 6
- 241000700721 Hepatitis B virus Species 0.000 claims description 33
- 239000013612 plasmid Substances 0.000 claims description 26
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 23
- 238000006731 degradation reaction Methods 0.000 claims description 19
- 230000015556 catabolic process Effects 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 claims description 13
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 claims description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 10
- 230000001588 bifunctional effect Effects 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 8
- 241000713666 Lentivirus Species 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 101150045797 hbp gene Proteins 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 230000000155 isotopic effect Effects 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 241001115402 Ebolavirus Species 0.000 claims description 2
- 241000724709 Hepatitis delta virus Species 0.000 claims description 2
- 241000156302 Porcine hemagglutinating encephalomyelitis virus Species 0.000 claims description 2
- 241000315672 SARS coronavirus Species 0.000 claims description 2
- 108020005202 Viral DNA Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 150000002972 pentoses Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 206010003445 Ascites Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 abstract description 19
- 230000029812 viral genome replication Effects 0.000 abstract description 19
- 230000008685 targeting Effects 0.000 abstract description 9
- 208000030507 AIDS Diseases 0.000 abstract description 5
- 208000002672 hepatitis B Diseases 0.000 abstract description 4
- 230000002452 interceptive effect Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 73
- 108090000623 proteins and genes Proteins 0.000 description 27
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 19
- 102100034574 P protein Human genes 0.000 description 18
- 101710181008 P protein Proteins 0.000 description 18
- 101710177166 Phosphoprotein Proteins 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 12
- 229960000980 entecavir Drugs 0.000 description 10
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000001819 mass spectrum Methods 0.000 description 9
- 102000044159 Ubiquitin Human genes 0.000 description 8
- 108090000848 Ubiquitin Proteins 0.000 description 8
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 8
- 238000010189 synthetic method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- -1 polymerase Proteins 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 108700024845 Hepatitis B virus P Proteins 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 102000011931 Nucleoproteins Human genes 0.000 description 4
- 108010061100 Nucleoproteins Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229950010131 puromycin Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101710203526 Integrase Proteins 0.000 description 3
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 229940079156 Proteasome inhibitor Drugs 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 101710109576 Terminal protein Proteins 0.000 description 3
- 102000018478 Ubiquitin-Activating Enzymes Human genes 0.000 description 3
- 108010091546 Ubiquitin-Activating Enzymes Proteins 0.000 description 3
- 101710086987 X protein Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000003207 proteasome inhibitor Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700739 Hepadnaviridae Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 description 2
- 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 description 2
- 108010005705 Ubiquitinated Proteins Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
- 229960003205 adefovir dipivoxil Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- MIUMFNVVSUWKLV-UHFFFAOYSA-N ethyl 10-hydroxydecanoate Chemical compound CCOC(=O)CCCCCCCCCO MIUMFNVVSUWKLV-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960005311 telbivudine Drugs 0.000 description 2
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 2
- 229960003560 tenofovir alafenamide fumarate Drugs 0.000 description 2
- SVUJNSGGPUCLQZ-FQQAACOVSA-N tenofovir alafenamide fumarate Chemical compound OC(=O)\C=C\C(O)=O.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 SVUJNSGGPUCLQZ-FQQAACOVSA-N 0.000 description 2
- 231100000033 toxigenic Toxicity 0.000 description 2
- 230000001551 toxigenic effect Effects 0.000 description 2
- 230000005758 transcription activity Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- FRIYHISQFBWFCN-UHFFFAOYSA-N 10-[(2-methylpropan-2-yl)oxy]-10-oxodecanoic acid Chemical compound CC(C)(C)OC(=O)CCCCCCCCC(O)=O FRIYHISQFBWFCN-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- ZXLYYQUMYFHCLQ-UHFFFAOYSA-N 2-methylisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(C)C(=O)C2=C1 ZXLYYQUMYFHCLQ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 108091036055 CccDNA Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 1
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 238000000504 luminescence detection Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960001355 tenofovir disoproxil Drugs 0.000 description 1
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 description 1
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5067—Liver cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/91245—Nucleotidyltransferases (2.7.7)
- G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
- G01N2333/9126—DNA-directed DNA polymerase (2.7.7.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
Abstract
一种涉及生物医药领域,具体而言涉及一类蛋白降解靶向嵌合体(PROTAC)化合物,其结构可用通式LGP‑LK‑LGE表示,其中LGP为结合脱氧核糖核酸(DNA)聚合酶的配体,LGE为结合E3泛素连接酶配体,LK为连结以上两种配体的桥链。该类化合物通过降解抑制病毒的脱氧核糖核酸(DNA)聚合酶而阻止病毒复制,杀灭病毒,进而起到治疗干预病毒感染性疾病如乙型肝炎及继发性疾病、获得性免疫缺陷综合症的作用。
Description
本发明涉及生物医药领域,具体而言涉及一类蛋白降解靶向嵌合体(PROTAC)化合物,其结构可用通式LGP-LK-LGE表示,其中LGP为结合脱氧核糖核酸(DNA)聚合酶的配体,LGE为结合E3泛素连接酶配体,LK为连结以上两种配体的桥链。该类化合物通过降解抑制病毒的脱氧核糖核酸(DNA)聚合酶而阻止病毒复制,杀灭病毒,进而起到治疗干预病毒感染性疾病如乙型肝炎及继发性疾病、获得性免疫缺陷综合症的作用。
很多病理过程可以归因于脱氧核糖核酸(DNA)复制的失控,包括病毒或细菌感染、自身免疫性疾病、肿瘤等。在DNA复制过程中,DNA聚合酶催化核苷酸单体以DNA或RNA为模板的聚合过程,形成长链聚合物核酸。对DNA聚合酶的调控是影响干预DNA复制的重要手段。病毒感染属于多发性疾病,包括肝炎、获得性免疫缺陷综合症(AIDS)、严重急性呼吸道综合征(SARS)等,其共同特点是伴随高度的病毒DNA合成。而作为DNA合成的关键酶,病毒内源性聚合酶是多种病毒维护生命周期的重要组成,这些病毒包括肝炎病毒、人类免疫缺陷病毒和流感病毒。病毒内源性DNA聚合酶是开发抗病毒药物的关键靶点。
乙型肝炎病毒(HBV)是一种DNA病毒,属于嗜肝DNA病毒科(hepadnavividae)。HBV可以引发急性和慢性肝炎,HBV感染也是导致肝癌和肝硬化的主要原因。世界卫生组织统计,全世界约有20亿人曾感染乙肝病毒,其中3.5多亿人为慢性感染患者,每年约有786000人死于HBV感染所致的肝衰竭、肝硬化和原发性肝细胞癌(HCC)。对HBV的分子生物学特性的研究为寻找基于新的作用机制的药物提供了帮助。HBV基因组为部分双链环状DNA,负链长大约为3.2kb,而正链长度约为负链的50-100%。其基因组包含四个开放阅读框(Open Reading Frame,ORF),分别对应为编码聚合酶(P蛋白)、核蛋白(C蛋白)、表面蛋白(S蛋白)以及X蛋白的基因。在这些HBV基因表达的蛋白中,聚合酶、表面蛋白和核蛋白是结构蛋白,而X蛋白具有调控功能。HBV聚合酶基因占全部病毒基因组的80%,并与其他基因的编码区重叠,根据基因型的不同可编码生成由832到845个氨基酸组成的P蛋白,即DNA聚合酶(Seeger C,Mason WS.Hepatitis B virus biology.Microbiol Mol Biol Rev.2000;64(1):51-68.)。该基因在病毒基因组复制中发挥着多重作用,其表达的DNA聚合酶(P蛋白)除了具有核酸复制的功能外,还作为必要的结构成分和衣壳蛋白、前基因组RNA及细胞因子等一起参与病毒包装形成未成熟病毒颗粒。HBV DNA聚合酶在肝细胞内作用合成DNA并附着到短链上从而形成HBV基因组完整的双螺旋,进一步通过RNA聚合酶的作用产生前基因组mRNA以及核蛋白、表面蛋白和调控蛋白(X蛋白)的mRNA,后者作为信使参与病毒蛋白翻译合成。
对HBV基因组开放读码框P区编码的氨基酸序列分析发现部分区域是高度保守的,与逆转录病毒的RNA依赖DNA多聚酶区及核糖核酸酶H(RNase H)区相似(Bartenschlager R,Schaller H.EMBO J.1992Sep;11(9):3413-20)。研究表明,构成HBV DNA聚合酶的4个结构域从5’末端开始,依次分别为末端蛋白区(TP domain)、间隔区(spacer)、逆转录酶区(RT domain)以及核糖核酸酶区(RNaseH domain)。这些不同的结构域与病毒复制过程的多个环节相关;其中末端蛋白具有多种功能,主要是在前基因组RNA反转录负链DNA时作为引物。末端蛋白也妨碍宿主细胞的干扰素诱导基因的激活,而抑制对干扰素的效应。DNA聚合酶在病毒基因组产生、与核蛋白和前基因组mRNA形成被称为复制体的结构方面具有重要功能。当复制体形成时,DNA负链由HBV聚合酶的反转录作用合成,而正链DNA链则通过DNA依赖的DNA聚合酶作用制成,其反过来又产生前基因组mRNA。DNA正链合成前,需要核糖核 酸酶H的活性以清除RNA-DNA杂交体中的RNA,留下单链DNA;降解形成的小片段RNA作为正链DNA合成的引物。对HBV DNA聚合酶逆转录区的氨基酸同源分析发现其包含5个主要的功能区域,他们分别为A区、B区、C区、D区和E区。其中A、C、D区为酶与三磷酸核苷结合区,而B、E区为RNA模板和引物定位区。DNA聚合酶的催化域位于C区的YMDD结构。这5个区域含有高度保守的氨基酸序列,是维持逆转录活性所必需的。
鉴于HBV DNA聚合酶在病毒逆转录乃至整个复制过程起到关键的作用,具备抑制聚合酶逆转录功能的核苷类化合物是目前用于治疗HBV感染的主要药物。其中包括拉米夫定(Lamivudine)、替比夫定(Telbivudine)、恩替卡韦(Entecavir)、阿德福韦酯(Adefovir Dipivoxil)、替诺福韦酯(Tenofovir disoproxil)和富马酸替诺福韦艾拉酚胺(Tenofovir alafenamide fumarate)等核(苷)酸类似物。这些核苷类似物是通过掺入聚合酶的DNA链,抑制HBV P蛋白的逆转录活性,不可逆地终止子代病毒HBV DNA新链的延伸、合成而阻止病毒繁殖。但是核苷类似物对cccDNA无明显影响,且并不减少前基因组RNA和mRNA,表明以DNA为模板的转录和病毒蛋白的转译不受药物影响。目前以聚合酶逆转录功能为靶点的治疗手段只能够抑制病毒的繁殖,还不能彻底清除HBV,达到治愈乙型肝炎的目的。另外核苷类药物也存在耐药性及停药后反弹的问题。因此寻找具有新作用机制的抗HBV药物是迫切需要解决的问题。由于HBV DNA聚合酶(P蛋白)在病毒生命周期多重阶段具有不同的功能,设计可以作用于HBV整体P蛋白进而阻断多重环节新类型药物是一个很有前景的发展方向。
在真核生物细胞内存在着两类主要的蛋白质降解途径:自噬(Autophagy)和泛素-蛋白酶体系统(ubiquitin proteasome system)。其中泛素-蛋白酶体途径是一种高效、特异的蛋白质降解过程,调控细胞内绝大多数蛋白质的降解。泛素化的蛋白质降解对于维持细胞中各种蛋白质的水平具有极其重要的作用,涉及了调节细胞周期、增殖、凋亡、转移、基因表达、信号传递等几乎一切生命活动。泛素蛋白是普遍存在于真核细胞内高度保守的蛋白,由76个氨基酸组成。泛素化的蛋白质可以被输送到26S蛋白酶体上或者进入溶酶体(lysosome)消化降解。蛋白质的泛素化是通过一系列的酶促反应来进行的。首先,泛素通过其C末端甘氨酸上的羧基和泛素活化酶(Ubiquitin activating enzyme)E1上的必需半胱氨酸巯基形成高能硫酯键而连接到E1上,成为活化状态的泛素;其次,活化的泛素从泛素活化酶E1转移到泛素结合酶(Ubiquitin conjugating enzyme)E2上;最后,在E3泛素连接酶(Ubiquitin ligase)的作用下,将连接在泛素结合酶E2上的泛素分子通过异构肽键的共价连接方式连接到底物蛋白上。泛素介导的蛋白降解特异性依靠泛素连接酶E3对底物蛋白特异的识别能力。
蛋白降解靶向嵌合体PROTAC(Proteolytic Targeting Chimera)技术利用了胞内的泛素-蛋白酶体系统降解特定的蛋白。技术特征为将可以结合靶向蛋白的小分子配体,和E3泛素连接酶的配体通过桥链片段连接起来,构成一个双功能化合物。通过调整优化连接方式,桥链的大小和其他理化性质,促使PROTAC分子两端的配体同时结合于靶蛋白与E3泛素连接酶,形成靶蛋白-PROTACs-E3连结酶三元复合物,进而使靶蛋白泛素化并被蛋白酶体系统降解。PROTAC技术具有可用于难成药蛋白降解、降解效力强以及在低浓度时即可保持催化降解作用等优势。同时,由于这一技术的蛋白降解模式为反复迭代,在靶蛋白突变等情况下相比传统的药物有更好的耐受性。PROTAC的技术难点在于靶蛋白配体,E3泛素连接酶配体的连接的构象和位点,桥链的长度和组成的修饰以及浓度等都会对三元复合物的形成及其稳定性产生影响,因此调控起来更具挑战性。
综上所述,鉴于这些病毒内源性DNA聚合酶在病毒复制过程中扮演的的重要角色,以及宿主细胞的泛素-蛋白酶体系统对特定蛋白降解的高效、特异性,本发明的目的是提供一类蛋白降解靶向嵌合体(PROTAC),该类分子可以特定地降解病毒内源性DNA聚合酶(P蛋白),从而在多重环节阻断病毒的复制,达到治疗病毒性感染疾病的目的。
发明内容
本发明涉及生物医药领域,具体而言涉及一类化合物或其药学上可接受的盐、溶剂化物、水合物、 多晶型物、互变异构体、几何异构体、同位素标记物、代谢产物或者前药。该类化合物通过降解抑制病毒的脱氧核糖核酸(DNA)聚合酶而阻止病毒复制,杀灭病毒,进而起到治疗干预病毒感染性疾病的作用。该类化合物属于蛋白降解靶向嵌合体(PROTAC),其结构可用通式LGP-LK-LGE表示,其中LGP为结合脱氧核糖核酸(DNA)聚合酶的配体,LGE为结合E3泛素连接酶配体,LK为连结以上两种配体的桥链(Linker),即分子官能团的组合。本发明提供了一类新型的脱氧核糖核酸(DNA)聚合酶降解抑制剂,可以起到有效干扰病毒存活复制的功能,治疗病毒感染引起的疾病,包括乙型肝炎及继发性疾病、获得性免疫缺陷综合症。
本发明提供的具有通式LGP-LK-LGE的一类蛋白降解靶向嵌合体在感染HBV的细胞内可以有效降解DNA聚合酶(P蛋白),并且能有效抑制HBV的复制。
本发明是通过以下方面实现的:
本发明的第一个方面:提供了一种双功能化合物,该类化合物为靶向蛋白降解嵌合体,其结构式如下:LGP-LK-LGE,其中LGP为结合脱氧核糖核酸(DNA)聚合酶的配体,LGE为结合E3泛素连接酶的配体,LK为连结以上两种配体LGP与LGE的桥链。
本发明的第二个方面:上述提供的化合物特征在于:结构式LGP-LK-LGE表示的化合物也包括其药学上可以接受的盐、溶剂化物、水合物、多晶型物、互变异构体、几何异构体、同位素标记物、代谢产物或者前药。
本发明的第三个方面:上述提供的化合物LGP-LK-LGE特征在于:结合脱氧核糖核酸(DNA)聚合酶的配体LGP可为如下任一结构,或者其羟基的磷酸化、双磷酸化、三磷酸化产物:
本发明的第四个方面:上述提供的化合物LGP-LK-LGE特征在于桥链LK通过化学键链接在LGP上;其特征还在于:所述LK链接在LGP的碱基上或者在LGP的环戊糖单元上;进一步优选地,链接位置为如下任一结构所示的位置:
本发明的第五个方面:上述提供的化合物LGP-LK-LGE结合E3泛素连接酶的配体LGE为任选取代的如下所示的结构:
其中,波折线表示与桥链LK通过化学键联接的部位;R
1任选是氢、氧或者任选C1-6烷基、C1-6 卤代烷基或者烷氧基;R
4任选是C1-6烷基、C1-6卤代烷基、或R
5CO-;R
5任选是C1-6烷基、C1-6卤代烷基;Y任选是C、O,S,NR
6;R
6任选C1-6烷基、C1-6卤代烷基或者烷氧基。
本发明的第六个方面:上述提供的化合物LGP-LK-LGE链接LGP与LGE两部分的桥链LK为任选的如下所示的结构:
其中,波折线表示桥链LK与LGP或者LGE通过化学键联接的部位;m任选为自然整数0-5;n任选为自然整数0-25;p任选为自然整数0-4;q任选为自然整数0-20;r任选为自然整数1-3;s任选为自然整数1-5。X任选是C、O,S,NR
2;R
2任选C1-6烷基、C1-6卤代烷基或者烷氧基。
本发明的第七个方面:上述提供的化合物LGP-LK-LGE为任选的如下所示的结构:
其中,m为自然整数0-5;n为自然整数0-25;s任选为自然整数1-5;q任选为自然整数0-20;R
2任选是氢、-P(O)(OH)
2,-P(O)OH-P(O)(OH)
2,或者-P(O)(OH)-P(O)(OH)-P(O)(OH)
2。
本发明的第八个方面:上述提供的化合物LGP-LK-LGE为任选的如下所示的结构:
其中,m为自然整数0-5;n为自然整数0-25;R
2任选是氢、-P(O)(OH)
2,-P(O)OH-P(O)(OH)
2,或者-P(O)(OH)-P(O)(OH)-P(O)(OH)
2。
其中,m为自然整数0-5;n为自然整数0-25;R
2任选是氢、-P(O)(OH)
2,-P(O)OH-P(O)(OH)
2,或者-P(O)(OH)-P(O)(OH)-P(O)(OH)
2;R
3任选是氢或者甲基。
本发明的第九个方面:上述提供的化合物LGP-LK-LGE为任选的如下所示的结构:
发明的第十个方面:上述提供的化合物LGP-LK-LGE为优先选择的如下所示的结构:
发明的第十一个方面:提供一种药物组合物,其特征在于,包括发明第一个方面到发明第十个方面任一项所述的化合物。
发明的第十二个方面:发明的第十一个方面所述药物组合物,其特征在于,进一步包含药学上可接受的载体、赋形剂、稀释剂、辅剂、媒介物或其组合。
发明的第十三个方面:发明的第十一个方面所述药物组合物,其特征在于,给药方式选自鼻服、吸入、局部、口服、肌内、皮下、经皮、腹腔、硬膜外、鞘内和静脉内途径中的至少一种。
发明的第十四个方面:发明第一个方面到发明第十个方面任一项所述的化合物明的制备方法,其特征在于:化合物(I)可由任选自以下两种合成路线制备:
其特征还在于:化合物(VI)可由以下合成路线制备:
发明的第十五个方面:发明第一个方面到发明第十个方面任一项所述的化合物或发明的第十一个方面所述药物组合物,其特征在于,能够降解抑制脱氧核糖核酸(DNA)聚合酶。
发明的第十六个方面:发明的第十一个方面所述药物组合物,其特征在于,能够优选的降解抑制病毒内源性脱氧核糖核酸(DNA)聚合酶。
发明的第十七个方面:发明的第十一个方面所述药物组合物,其特征在于,能够更优选的降解抑制嗜肝DNA病毒科(Hepadnaviridae)所属病毒内源性脱氧核糖核酸(DNA)聚合酶。
发明的第十八个方面:发明的第十一个方面所述药物组合物,其特征在于,能够更优选的降解乙型肝炎病毒病毒内源性脱氧核糖核酸(DNA)聚合酶。
发明的第十九个方面:发明第一个方面到发明第十个方面任一项所述的化合物或发明的第十一个方面所述的药物组合物在降解抑制脱氧核糖核酸(DNA)聚合酶过程中的用途。
发明的第二十个方面:发明第一个方面到发明第十个方面任一项所述的化合物或发明的第十一个方 面所述的药物组合物在制备降解抑制脱氧核糖核酸(DNA)聚合酶药物中的用途。
发明的第二十一个方面:发明第一个方面到发明第十个方面任一项所述的化合物或发明的第十一个方面所述的药物组合物用于治疗、预防或诊断与脱氧核糖核酸聚合酶相关的各种疾病中的应用,所述疾病包括但不限于病毒感染性疾病及由病毒感染引起的继发性疾病,所述病毒感染性疾病由乙型肝炎病毒、人类免疫缺陷病毒、HCV、HDV、HEV、埃博拉病毒、SARS病毒、COVID19感染所致,所述继发性疾病包括但不限于:肝硬化、肝纤维化、肝癌。
发明的第二十二个方面:一种同时表达LgBiT和HiBiT并且高表达HBP基因的细胞系Huh7-HBP,其特征在于,具有HBP基因,并且优选地由以下方法制备:
(1)将LgBiT标签核苷酸序列插入慢病毒载体pCDH-CMV-EF1a-Neo,得到重组质粒pCDH-CMV-LgBiT-EF1a-Neo,将所述重组质粒pCDH-CMV-LgBiT-EF1a-Neo连同慢病毒辅助质粒pMD2.G和pSPAX2一起进行慢病毒包装,将包装完成的慢病毒转导Huh7细胞系,得到新的细胞系Huh7-LgBiT;
(2)N端带有HiBiT标签的目的基因HBP的序列插入慢病毒载体pLVX-Puro载体中,得到重组质粒pLVX-HBP-Puro,将所述重组质粒pLVX-HBP-Puro连同慢病毒辅助质粒pMD2.G和pSPAX2一起进行慢病毒包装,将包装完成的慢病毒转导Huh7-LgBiT细胞系,得到同时表达LgBiT和HiBiT并且高表达HBP基因的细胞系Huh7-HBP。
发明的第二十三个方面:如发明的第二十二个方面所述的细胞系Huh7-HBP在测定细胞内病毒DNA聚合酶的含量中的用途。
图1:本发明化合物(I)的
1H NMR光谱图;
图2:本发明化合物(I)的质谱图;
图3:本发明化合物(I)的高效液相谱图;
图4:化合物(VI)的1H NMR图;
图5:化合物(VI)的质谱图;
图6:化合物(VI)的高效液相谱图;
图7:化合物(I)(TPD00203)在HepG2.2.15细胞阻止病毒复制的作用(7天);
图8:化合物(I)(TPD00203)在HepAD38细胞中阻止病毒复制的作用(7天);
图9:化合物(I)(TPD00203)在HepAD38细胞中与相同浓度阳性对照药物(ETV)阻止病毒复制作用比较(7天);
图10:化合物(I)(TPD00203)在过度表达Flag-多聚酶的Huh7细胞中对P蛋白的降解36-48小时实验;
图11:化合物(I)(TPD00203)在过度表达Flag-多聚酶的Huh7细胞中对P蛋白的降解30-36小时实验;
图12:质粒序列与图谱PLVX-HBP-HiBiT-Puro;
图13:质粒序列与图谱pCDH-CMV-LgBiT-EF1a-Neo;
图14:化合物(I)在Huh7-HBP细胞系中对HBP蛋白降解作用。
下面结合本发明实施例中的附图通过具体实施例进一步说明本发明。但是这些实施例仅仅是用于更详细的具体说明用,而不应理解为用于以任何形式限制本发明。本发明可以由权利要求限定和覆盖的多种不同方式实施。
本发明对试验中所使用到的材料以及实验方法进行一般性和具体性的描述。虽然为实现本发明的目 的所使用的许多材料和操作方法是本领域公知的,但是本发明仍然在此作尽可能详细的描述。在下文中,如未特别说明,所使用的材料和操作方法是本领域公知的。
除非另外定义,本发明中使用的所有术语(包括技术术语和科学术语)均具有如本发明所属领域的普通技术人员通常理解的相同含义。
实施例1:靶向降解DNA聚合酶的化合物(I)的合成与结构确认。
目标化合物(I,TPD00203)经由如下合成路线制备:
2-氨基-9-[(1S,3S,4S)-4-叔丁基二甲基硅氧基-3-叔丁基二甲基硅氧基甲基-2-亚甲基环戊基]-1,9-氢-嘌呤-6-醇(化合物2):室温下将2-氨基-9-[(1S,3S,4S)-4-羟基-3-羟甲基-2-亚甲基环戊基]-1,9-氢-嘌呤-6-醇(700mg,2.52mmol)和DMAP(16mg,0.13mmol)溶于吡啶(20mL)中,室温下慢慢加入TBDMSCl(950mg,6.30mmol),反应液于50℃条件下反应24小时。冷却到室温后,倒入水中,用乙酸乙酯萃取两次,水洗两次,饱和食盐水洗涤两次,无水硫酸钠干燥过滤,过滤,有机相旋干,上制备板分离得到500mg化合物2(收率:39%)。产品性状为白色固体。
乙基10-((2-氨基-9-[(1S,3S,4S)-4-叔丁基二甲基硅氧基-3-叔丁基二甲基硅氧基甲基-2-亚甲基环戊基]-9-氢-嘌呤-6-氧基癸酸酯(化合物7):室温下将化合物2(500mg,0.99mmol溶于THF(10mL)中,依次加入乙基10-羟基癸酸酯(化合物6)(257mg,1.19mmol)、PPh
3(391mg,1.49mmol)、DIAD(301mg,1.49mmol)。反应液置换氮气后于室温反应24小时。倒入水中,用乙酸乙酯萃取两次,水洗两次,饱和食盐水洗涤两次,无水硫酸钠干燥过滤,有机相旋干,上制备板分离得到430mg化合物7(收率:62%)。
10-(2-氨基-9-[(1S,3S,4S)-4-叔丁基二甲基硅氧基-3-叔丁基二甲基硅氧基甲基)-2-亚甲基环戊基]-9-氢-嘌呤-6-氧基癸酸(化合物8):室温下将化合物7(430mg,0.61mmol溶于EtOH(10mL)中,加入LiOH﹒H2O(77mg,1.83mmol)。反应液于室温反应12小时。旋干加水溶解,用柠檬酸酸化到pH 4,用DCM萃取两次,水洗两次,无水硫酸钠干燥过滤,有机相旋干得370mg化合物8(收率:90%)。
(2S,4R)-1-((S)-2-(10-((2-氨基-9-[(1S,3S,4S)-4-叔丁基二甲基硅氧基-3-叔丁基二甲基硅氧基甲基-2-亚甲基环戊基]-9-氢-嘌呤-6-烷基氧)癸酰胺)-3,3-二甲基丁酰基)-N-(4-(4-甲基噻唑-5-烷)苄基)吡咯烷-2-甲酰胺(化合物5):室温下将化合物8(370mg,0.54mmol和(2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰)-4-羟基-N-(4-(4-甲基噻唑-5-烷)苄基)吡咯烷-2-甲酰胺(化合物3,252mg,0.54mmol)溶于DCM(10mL)中,依次加入HOBT(109mg,0.81mmol),EDCI(155mg,0.81mmol),DIEA(279mg,2.16mmol)。反应液于室温反应12小时。加水淬灭反应,用DCM萃取两次,水洗两次,无水硫酸钠干燥过滤,有机相旋干后粗品用制备HPLC分离得到230mg化合物5(收率:39%)。
(2S,4R)-1-((S)-2-(10-((2-氨基-9-[(1S,3S,4S)-4-羟基-3-羟甲基-2-亚甲基环戊基]-9-氢-嘌呤-6-烷基氧)癸酰胺)-3,3-二甲基丁酰基)-N-(4-(4-甲基噻唑-5-烷)苄基)吡咯烷-2-甲酰胺(化合物I)(TPD00203):室温下将化合物8(230mg,0.21mmol溶于THF(10mL)中,加入TBAF(220mg,0.84mmol),反应液于室温反应12小时,有机相旋干,粗品用制备HPLC分离得到103mg白色固体化合物(I)(收率:57%)。
目的化合物(I,TPD00203)结构和纯度经过核磁共振谱,质谱以及高效液相色谱确证无误,高效液相色谱确证预期化合物(I,TPD00203)纯度高于95%(参见图1至图3)。
实施例2:化合物II-V的合成与结构确认
2.1目的化合物II采用与化合物I相同的合成方法制备,但是化合物I合成中采用的中间体化合物6被如下中间体代替:
2.2目的化合物III采用与化合物I相同的合成方法制备,但是化合物I合成中采用的中间体化合物6被如下中间体代替:
2.3目的化合物IV采用与化合物I相同的合成方法制备,但是化合物I合成中采用的中间体化合物6被如下中间体代替:
2.4目的化合物V采用与化合物I相同的合成方法制备,但是化合物I合成中采用的中间体化合物6被如下中间体代替
以上化合物结构经过核磁共振谱,质谱,以及高分辨质谱确证无误;纯度经过高效液相色谱测定。 数据结果见实施例5表格。
实施例3:靶向降解DNA聚合酶的化合物(VI)的合成与结构确认
目标化合物(VI)经由如下合成路线制备
((1R,3S)-3-(2-氨基-6-氧-1,6-二氢-9H-嘌呤-9-基)-5-羟基-2-亚甲基环戊基)甲基4-甲基苯磺酸酯(化合物9):将2-氨基-9-[(1S,3S,4S)-4-羟基-3-羟甲基-2-亚甲基环戊基]-1,9-氢-嘌呤-6-醇(4g,14.4mmol)和TosCl(3.57g,18.72mmol)在吡啶(30mL)中25℃下搅拌过夜。反应完成后将反应液减压浓缩,得到黄色油状粗品化合物9(11.8g,收率57%)。该粗品直接用于下步反应。
2-(((1R,3S)-3-(2-氨基-6-羟基-9H-嘌呤-9-基)-5-羟基-2-2-亚甲基环戊基)甲基异吲哚啉-1,3-二酮(化合物10):将化合物9(11.8g,27.3mmol)、邻苯二甲酰亚胺(6.03g,40.9mmol)和碳酸钾(7.55g,54.6mmol)溶于DMF(110mL)中,50℃反应16小时。反应完成后,过滤,滤液高压制备液相纯化得到灰色固体化合物10(0.32g,纯度95%)。
2-氨基-9-((1S,3R)-3-(氨甲基)-4-羟基-2-亚甲基环戊基)-1,9-二氢-6H-嘌呤-6-酮(化合物11):化合物10(280mg,0.69mmol)溶于MeOH(5mL)中,加入水合肼(172.5mg,1.38mmol),25℃反应2小时。反应完成将反应液倒入MTBE中(30mL),产品析出,过滤得棕色固体化合物11(150mg,纯度90%,收率71%)。
叔丁基10-(((S)-1-((2S,4R)-4-羟基-2-((4-(4-甲基噻唑-5-基)卞基)氨基甲酰)吡咯烷-1-基)-3,3-二甲基-1-氧丁烷-2-y基)胺基)-10-氧癸酸酯(化合物12):将(2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰)-4-羟基-N-(4-(4-甲基噻唑-5-烷)苄基)吡咯烷-2-甲酰胺(化合物3,200mg,0.46mmol)、10-(叔丁氧基)-10-氧代癸酸(化合物14,144mg,0.56mmol)、HOBT(94.1mg,0.70mmol),EDCI(133.6mg,0.70mmol)和三乙胺(141mg,1.39mmol)溶于DMF(5mL)中,25℃反应16小时。反应完成后将反应液加入冰水(30mL)中,并用乙酸乙酯(20mL x 2)萃取,有机层用Na
2SO
4干燥并浓缩,TLC板分得到黄色油状化合物12(230mg,纯度95%,收率70%)。
10-(((S)-1-((2S,4R)-4-羟基-2-((4-(4-甲基噻唑-5-基)卞基)氨基甲酰)吡咯烷-1-基)-3,3-二甲基-1-氧丁烷-2-基)胺基)-10-氧癸酸(化合物13):将化合物12(200mg,0.30mmol)溶于(5mL)DCM中,加入TFA(339.9mg,2.98mmol),25℃反应1小时。反应完成真空旋干溶剂得到黄色油状化合物13(150mg,纯度95%,收率68%)。
N1-(((1R,3S)-3-(2-氨基-6-氧-1,6-二氢-9H-嘌呤-9-基)-5-羟基-2-亚甲基环戊基)甲基)-N10-((S)-1-((2S,4R)-4-羟基-2-((4-(4-甲基噻唑-5-基)卞基)氨基甲酰)吡咯烷-1-基)-3,3-二甲基-1-氧丁烷-2-基)癸酸二酰胺(化合物VI):化合物13(120mg,0.43mmol)和化合物11(320.4mg,0.52mmol)溶于DMF(3mL)中,室温下加入HOBT(88.02mg,0.65mmol)、EDCI(124.9mg,0.65mmol)和TEA(131.8mg,1.30mmol),反应液25℃反应16小时。反应液高压液相制备纯化得白色固体(VI,30mg,纯度96%,收率14%)。目的化合物(VI)结构和纯度经过核磁共振谱,质谱以及高效液相色谱确证无误,高效液相色谱确证预期化合物(VI)纯度高于95%(参见图4至图6)。
实施例4:化合物VII-X的合成与结构确认
4.1目的化合物VII采用与化合物VI相同的合成方法制备,但是化合物VI合成中采用的中间体化合物14被如下中间体代替:
4.2目的化合物VIII采用与化合物VI相同的合成方法制备,但是化合物VI合成中采用的中间体化合物14被如下中间体代替:
4.3目的化合物IX采用与化合物VI相同的合成方法制备,但是化合物VI合成中采用的中间体化合物14被如下中间体代替:
4.4目的化合物X采用与化合物VI相同的合成方法制备,但是化合物VI合成中采用的中间体化合物6被如下中间体代替
以上化合物结构经过核磁共振谱,质谱,以及高分辨质谱确证无误;纯度经过高效液相色谱测定。数据结果见实施例5表格。
实施例5:化合物I-X的质谱,高分辨质谱及高效液相分析结果
实施例6化合物(I,TPD00203)对不同细胞系中HBV病毒复制抑制实验
体外细胞模型1:乙型肝炎病毒(HBV)转染的HepG2细胞,即HepG2 2.2.15细胞。
体外细胞模型2:稳定产毒的HepAD38细胞。
阳性药物对照:恩替卡韦(ETV)。
试验过程:将HepG2.2.15和稳定产毒的HepAD38细胞分为六个实验组。每孔细胞数7x10
4个,每孔培养基用量500μl。第一组为空白对照,第二组为阳性对照,加入3.75nM的ETV;第三组到第六组分别加入3.75nM、100nM、5μM和100μM化合物(I,TPD00203)。加药后第3天收集上清液并检测上清液中HBV DNA水平。第7天再次收集上清液并细胞沉淀,检测上清中HBV DNA水平。
实验结果:对HBV复制的抑制效果见图7~图8。在HepG2.2.15细胞系中,给药7天后,恩替卡韦组显示了明显的病毒复制抑制作用(P≤0.001);TPD00203给药组与空白组相比在3.75nM(P≤0.001)、5μM(P≤0.001)和100μM(P≤0.001)三个剂量都显示了明显的病毒复制抑制作用(图7)。在HepAD38细胞系中,给药7天后各个剂量组以及阳性对照组都显示了明显的对病毒复制抑制效果(图8)。
在初步对TPD00203抑制病毒效果评估后,又在HepAD38细胞系中对相同剂量的TPD00203与ETV的抑制作用进行了比较测定。ETV和TPD00203均为10nM、100nM、1μM、10μM 4个剂量组。7天的实验结果显示ETV和TPD00203在测试各个剂量水平都可以明显抑制病毒复制(P≤0.001),并且在相同剂量情况下TPD00203抑制病毒效果优于ETV(图9)。
实施例7化合物(I-X)在HepAD38细胞系中对HBV病毒复制抑制活性结果
化合物(I-X)在HepAD38细胞系对病毒的抑制活性以实施例6相同的方法测定,结果见下表。
*+++对病毒复制呈现>60%抑制活性;++对病毒复制呈现30-60%抑制活性;+对病毒复制呈现10-30%抑制活性
实施例8化合物(I,TPD00203)对Huh7细胞系中HBV P蛋白降解作用
体外细胞模型:Huh7.
蛋白酶体抑制剂:MG132
使用含10uM TPD00203药物的培养基培养的Huh7细胞转染含flag标签的P蛋白过表达质粒,转染后6小时换为含10μM TPD00203药物的培养基,转染后24小时加入MG132(终浓度10μM)抑制P蛋白降解,MG132处理12小时后收细胞。MG132是可逆的蛋白酶体抑制剂,撤去MG132后再用含10μM TPD00203药物的培养基培养12小时,收细胞。进行Western Blot实验检测P蛋白表达情况。以DMSO作为对照。
实验结果:在Huh7细胞中转染flag-Polymerase质粒,并在转染后24小时加入蛋白酶体抑制剂MG132抑制P蛋白的降解。在转染后36小时可以观察到TPD00203促进P蛋白降解,并且MG132会抑制药物的降解作用。P蛋白降解迅速,在转染后48小时的P蛋白表达水平低于转染后36小时。MG132的蛋白酶体抑制作用可逆,在撤药后,细胞内蓄积的P蛋白会继续降解(图10-图11)。
实施例9 表达LgBiT和HiBiT,同时高表达HBP基因的细胞系(Huh7-HBP)的构建
细胞系构建流程:
9.1目的质粒pCDH-CMV-LgBiT-EF1a-Neo获取
首先,通过基因合成的方式获得LgBiT标签核苷酸序列,并且序列两端带有Nhe I和BamH I酶切位点。序列合成完成后,通过双酶切、连接方式将该序列插入慢病毒载体pCDH-CMV-EF1a-Neo,重组质粒命名为pCDH-CMV-LgBiT-EF1a-Neo。该重组质粒采用CMV启动子,并带有新霉素抗性基因。
9.2慢病毒包装
将目的质粒pCDH-CMV-LgBiT-EF1a-Neo连同慢病毒辅助质粒pMD2.G和pSPAX2一起,进行慢病毒包装。慢病毒包装流程如下:
将已长到80%-90%的293FT细胞培养瓶(T175)从37℃5%CO
2的细胞培养箱中取出,加入2mL TrypLETM EXPRESS消化后收集洗涤细胞,并将细胞重新铺145mm平皿,加20mL DMEM培养基(Thermo Fisher),轻轻摇匀,使细胞大约覆盖平皿的80%,放入37℃,5%CO
2培养箱中培养。
24小时后,将三个质粒与转染试剂PEI-Pro(polyplus,货号:29031C1B)混合均匀,室温静置10min。将用于包装病毒的293FT细胞从37℃5%CO
2的细胞培养箱中取出,将上述混合液平均加到每平皿中,轻轻摇匀,放入37℃5%CO
2培养箱中。4h后,弃旧培养基,加入5mL已预热的PBS清洗细胞,再加入20mL新鲜的已预热的含10%胎牛血清的DMEM培养基,放入37℃5%CO
2培养箱中培养。
继续培养48h-72h后收取培养上清作为病毒原液。将原液高速离心2h。将上清液弃净,加入无血清培养基重悬病毒颗粒。加入的培养基体积:病毒原液体积=1:500。此即为病毒浓缩液。将病毒浓缩液按100μl/管分装,另外留取10μl进行病毒滴度测定。将分装好的浓缩液置于-80℃保存。
9.3 Huh7-LgBiT细胞系构建
构建阳性细胞系前,首先进行抗生素耐受性的测试。将铺有Huh7细胞系的24孔板中加入含有不同浓度的G418(MCE,HY-17561)DMEM+10%FBS完全培养基,当G418浓度到达300ug/ml时,Huh7细胞全部死亡。证明该浓度为空白Huh7最大耐受浓度,后续阳性细胞系用该浓度进行筛选。
将包装完成的慢病毒进行Huh7细胞系的转导:
Day1:按照2E5/孔将Huh7细胞系铺6孔板;
Day2:按20ul/孔加入LgBiT慢病毒,轻轻混匀;
Day3:按照预先测试出的抗生素浓度加入到转导后的细胞系中,同时做空白Huh7的对照。
当对照组细胞全部死亡,实验组细胞仍有存活时停止筛选。实验组细胞系继续进行培养,同时加入300ug/ml的G418。
9.4 PLVX-HBP-Puro质粒的构建
首先,通过基因合成的方式获得N端带有HiBiT标签的目的基因HBP的序列,并且两端带有Xho I和BamH I酶切位点,序列合成完成后,通过双酶切、连接方式将该序列插入慢病毒载体pLVX-Puro载体中,重组质粒命名为pLVX-HBP-Puro。该重组质粒采用CMV启动子,并带有嘌呤霉素抗性基因。
9.5慢病毒包装
将目的质粒pLVX-HBP-Puro连同慢病毒辅助质粒pMD2.G和pSPAX2一起,进行慢病毒包装。包装流程同9.2。
9.6 Huh7-HBP
构建阳性细胞系前,首先进行抗生素耐受性的测试。将铺有Huh7-LgBiT细胞系的24孔板中加入含有不同浓度的嘌呤霉素(InvivoGen,ant-pr-1)DMEM+10%FBS完全培养基,当嘌呤霉素浓度到达2ug/ml时,Huh7-LgBiT细胞全部死亡。证明该浓度为Huh7-LgBiT最大耐受浓度,后续阳性细胞系用该浓度进行筛选。
将包装完成的慢病毒进行Huh7-LgBiT细胞系的转导:
Day1:按照2E5/孔将Huh7-LgBiT细胞系铺6孔板;
Day2:按20ul/孔加入HBP-HiBiT慢病毒,轻轻混匀;
Day3:按照预先测试出的抗生素浓度加入到转导后的细胞系中,同时做Huh7-LgBiT的对照。
当对照组细胞全部死亡,实验组细胞仍有存活时停止筛选。实验组细胞系继续进行培养,同时加入2ug/ml的嘌呤霉素。最终获得同时表达LgBiT和HiBiT,并且高表达HBP基因的细胞系Huh7-HBP。
HBP序列参考:UniProt ID P03156。
LgBiT序列:SEQ ID No.1
HiBiT序列来自于Promega公司,通过https://promega.formstack.com/forms/hibit_synthesis_licensing_agreement
查看并同意相关使用条款可以获得HiBiT序列。
实施例10化合物(I-X)在构建的Huh7-HBP细胞系中对HBV P蛋白降解作用.
一:Huh7-HBP细胞系中测定HBVP蛋白浓度试验步骤:
将转染好的huh-7-HBP细胞系消化悬浮,以2x10^5/ml的浓度,在96孔板中每孔加入100ul细胞悬液,孵育过夜。按照提前设定的剂量在每孔加入10ul药物,每个药物的每个剂量应至少两个复孔。轻轻震荡,然后重新放入培养箱内,根据具体情况选择孵育1-24h。将
Live Cell Assay System试剂盒中
LCS Dilution Buffer与
Live Cell Substrate两种试剂按照20:1混匀,按照每100ul体系加入25ul的比例加入到待检测细胞板中。震荡30秒,使用BMG Labtech FLUOstar Omega酶标仪进行全波长发光度检测。所测发光值越高,表明目标蛋白HBP含量越高。
二:Huh7-HBP细胞系中HBVP蛋白(即DNA聚合酶)降解实验结果:
根据方法一所述测定了目的化合物I-X在5个不同浓度对HBV P蛋白的降解作用。化合物I-X均呈现不同程度的P蛋白降解作用。参见附图14及下表。
*+++蛋白降解>70%;++蛋白降解30-70%;+蛋白降解<30%
综上所述,本发明提供了一种可有效降解HBV DNA聚合酶的新型PROTAC化合物。实验结果表明,该类化合物可通过降解病毒的DNA聚合酶达到阻止病毒复制的目的,为有效治疗病毒性感染疾病提供了一个的解决方案。
Claims (12)
- 一种双功能化合物及其药学上可接受的盐、溶剂化物、水合物、多晶型物、互变异构体、几何异构体、同位素标记物、代谢产物或者前药,其特征在于,所述双功能化合物具有LGP-LK-LGE的结构,其中LGP为结合脱氧核糖核酸(DNA)聚合酶的配体,LGE为结合E3泛素连接酶的配体,LK为连接LGP与LGE的桥链。
- 根据权利要求1所述的双功能化合物,其特征在于:所述LGP选自以下结构组成的组,或者选自在以下任一结构的羟基处磷酸化、双磷酸化或三磷酸化后的结构组成的组:
- 根据权利要求1所述的双功能化合物,其特征在于:所述LGE选自如下所示的结构组成的组:其中,波折线表示与LK通过化学键链接的部位;R 1任选是氢、氧或者任选C1-6烷基、C1-6卤代烷基或者烷氧基;R 4任选是C1-6烷基、C1-6卤代烷基或R 5CO-;R 5任选是C1-6烷基、C1-6卤代烷基;Y任选是C、O、S、NR 6;R 6任选C1-6烷基、C1-6卤代烷基或者烷氧基。
- 根据权利要求1所述的双功能化合物,其特征在于:所述LK任选地具有如下所示的结构:其中,波折线表示桥链LK与LGP或者LGE通过化学键联接的部位;m任选为自然整数0-5;n任选为自然整数0-25;p任选为自然整数0-4;q任选为自然整数0-20;r任选为自然整数1-3;s任选为自然整数1-5,X任选是C、O、S、NR 2;R 2任选C1-6烷基、C1-6卤代烷基或者烷氧基;优选地,所述LK通过化学键链接在LGP上;更优选地,所述LK链接在LGP的碱基上,进一步优选地,链接位置为如下任一结构所示的位置:或者优选地,所述LK链接在LGP的环戊糖单元上,进一步优选地,链接位置为如下任一结构所示的位置:
- 根据权利要求1-4任一项所述的双功能化合物,其特征在于,所述LGP-LK-LGE任选地具有如下所示的结构:其中,m为自然整数0-5,n为自然整数0-25,s任选为自然整数1-5,q任选为自然整数0-20,R 2任选是氢、-P(O)(OH) 2、-P(O)OH-P(O)(OH) 2或者-P(O)(OH)-P(O)(OH)-P(O)(OH) 2;或其中,m为自然整数0-5,n为自然整数0-25,R 2任选是氢、-P(O)(OH) 2、-P(O)OH-P(O)(OH) 2或者-P(O)(OH)-P(O)(OH)-P(O)(OH) 2;或其中,m为自然整数0-5,n为自然整数0-25,R 2任选是氢、-P(O)(OH) 2、-P(O)OH-P(O)(OH) 2或者-P(O)(OH)-P(O)(OH)-P(O)(OH) 2,R 3任选是氢或者甲基;或根据权利要求1-4任一项所述的双功能化合物LGP-LK-LG优先选自具有如下所示的结构:
- 包括权利要求1-5任一项所述的双功能化合物的药物组合物。
- 根据权利要求6所述的药物组合物,其特征在于,还进一步包含药学上可接受的载体、赋形剂、稀释剂、辅剂、媒介物或其组合。
- 权利要求1-5任一项所述的化合物的制备方法,其特征在于,所述化合物(I)可由任选自以下两种合成路线制备:路线(1):路线(2):或者,所述化合物(VI)可由以下合成路线制备:
- 权利要求1-5任一项所述的双功能化合物或权利要求6-7任一项所述的药物组合物用于制备降解抑制脱氧核糖核酸(DNA)聚合酶的药物中的用途,所述脱氧核糖核酸(DNA)聚合酶优选为病毒内源性脱氧核糖核酸(DNA)聚合酶,更优选为乙型肝炎病毒病毒内源性脱氧核糖核酸(DNA)聚合酶,进一步优选为嗜肝DNA病毒科(Hepadnaviridae)病毒内源性脱氧核糖核酸(DNA)聚合酶。
- 权利要求1-5任一项所述的双功能化合物或权利要求6-7任一项所述的药物组合物用于治疗、预防或诊断与脱氧核糖核酸聚合酶相关的各种疾病中的应用,所述疾病包括但不限于病毒感染性疾病及其继发性疾病,优选地,所述病毒感染性疾病为乙型肝炎病毒、人类免疫缺陷病毒、HCV、HDV、HEV、埃博拉病毒、SARS病毒、COVID19感染所致;所述病毒感染引起的继发性疾病优选为肝硬化、肝纤维化、肝腹水或肝癌。
- 一种同时表达LgBiT和HiBiT并且高表达HBP基因的细胞系Huh7-HBP,其特征在于,具有HBP基因,并且优选地由以下方法制备:(1)将LgBiT标签核苷酸序列插入慢病毒载体pCDH-CMV-EF1a-Neo,得到重组质粒pCDH-CMV-LgBiT-EF1a-Neo,将所述重组质粒pCDH-CMV-LgBiT-EF1a-Neo连同慢病毒辅助质粒pMD2.G和pSPAX2一起进行慢病毒包装,将包装完成的慢病毒转导Huh7细胞系,得到新的细胞系Huh7-LgBiT;(2)N端带有HiBiT标签的目的基因HBP的序列插入慢病毒载体pLVX-Puro载体中,得到重组质粒pLVX-HBP-Puro,将所述重组质粒pLVX-HBP-Puro连同慢病毒辅助质粒pMD2.G和pSPAX2一起进行慢病毒包装,将包装完成的慢病毒转导Huh7-LgBiT细胞系,得到同时表达LgBiT和HiBiT并且高表达HBP基因的细胞系Huh7-HBP。
- 如权利要求11所述的细胞系Huh7-HBP在测定细胞内病毒DNA聚合酶的含量中的用途。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021100940888 | 2021-01-22 | ||
CN202110094088 | 2021-01-22 | ||
CN2022100643104 | 2022-01-20 | ||
PCT/CN2022/073159 WO2022156764A1 (zh) | 2021-01-22 | 2022-01-21 | 一种降解脱氧核糖核酸(dna)聚合酶的化合物及其用途 |
CN202210064310.4A CN116554174A (zh) | 2021-01-22 | 2022-06-08 | 一种降解脱氧核糖核酸(dna)聚合酶的化合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116802180A true CN116802180A (zh) | 2023-09-22 |
CN116802180B CN116802180B (zh) | 2024-05-28 |
Family
ID=82548512
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280011048.5A Active CN116802180B (zh) | 2021-01-22 | 2022-01-21 | 一种降解脱氧核糖核酸(dna)聚合酶的化合物及其用途 |
CN202210064310.4A Pending CN116554174A (zh) | 2021-01-22 | 2022-06-08 | 一种降解脱氧核糖核酸(dna)聚合酶的化合物及其用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210064310.4A Pending CN116554174A (zh) | 2021-01-22 | 2022-06-08 | 一种降解脱氧核糖核酸(dna)聚合酶的化合物及其用途 |
Country Status (3)
Country | Link |
---|---|
CN (2) | CN116802180B (zh) |
WO (1) | WO2022156764A1 (zh) |
ZA (1) | ZA202307894B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116554174A (zh) * | 2021-01-22 | 2023-08-08 | 泰比棣医药科技(石家庄)有限公司 | 一种降解脱氧核糖核酸(dna)聚合酶的化合物及其用途 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116297415B (zh) * | 2023-05-11 | 2023-08-18 | 细胞生态海河实验室 | 一种protac药物的筛选方法及载体 |
CN117229260B (zh) * | 2023-11-13 | 2024-02-27 | 中国药科大学 | DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103635576A (zh) * | 2011-06-30 | 2014-03-12 | 箭头研究公司 | 用于抑制乙型肝炎病毒的基因表达的组合物和方法 |
WO2016146985A1 (en) * | 2015-03-13 | 2016-09-22 | University Of Dundee | Derivatives of 1-[(cyclopentyl or 2-pyrrolidinyl)carbonylaminomethyl]-4-(1,3-thiazol-5-yl) benzene which are useful for the treatment of proliferative, autoimmune or inflammatory diseases |
US20170037004A1 (en) * | 2015-07-13 | 2017-02-09 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
CN108601764A (zh) * | 2015-03-18 | 2018-09-28 | 阿尔维纳斯股份有限公司 | 用于靶蛋白的增强降解的化合物和方法 |
CN110072866A (zh) * | 2016-09-13 | 2019-07-30 | 密执安大学评议会 | 作为bet蛋白降解剂的稠合的1,4-二氮杂* |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1289510C (zh) * | 2003-06-27 | 2006-12-13 | 成都地奥制药集团有限公司 | 一种具有抗病毒活性的化合物及其制备方法 |
CN103881979B (zh) * | 2014-03-20 | 2016-02-24 | 北京大学 | 抗丙肝病毒药物高通量筛选模型及其应用 |
CN110812472B (zh) * | 2019-11-19 | 2022-10-21 | 福建医科大学 | E3泛素连接酶stub1在抑制乙型肝炎病毒复制中的应用 |
CN113563414B (zh) * | 2020-04-29 | 2022-08-12 | 泰比棣医药科技(石家庄)有限公司 | 一种组织靶向的蛋白靶向降解化合物及其用途 |
CN113321700B (zh) * | 2020-06-02 | 2022-07-01 | 泰比瑞医药科技(石家庄)有限公司 | 一种降解靶蛋白的双功能化合物及其用途 |
US20230323369A1 (en) * | 2020-06-24 | 2023-10-12 | Xiamen University | Screening model and method for hbv cccdna-targeting drug |
WO2022156764A1 (zh) * | 2021-01-22 | 2022-07-28 | 泰比棣医药科技(石家庄)有限公司 | 一种降解脱氧核糖核酸(dna)聚合酶的化合物及其用途 |
-
2022
- 2022-01-21 WO PCT/CN2022/073159 patent/WO2022156764A1/zh active Application Filing
- 2022-01-21 CN CN202280011048.5A patent/CN116802180B/zh active Active
- 2022-06-08 CN CN202210064310.4A patent/CN116554174A/zh active Pending
-
2023
- 2023-08-14 ZA ZA2023/07894A patent/ZA202307894B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103635576A (zh) * | 2011-06-30 | 2014-03-12 | 箭头研究公司 | 用于抑制乙型肝炎病毒的基因表达的组合物和方法 |
WO2016146985A1 (en) * | 2015-03-13 | 2016-09-22 | University Of Dundee | Derivatives of 1-[(cyclopentyl or 2-pyrrolidinyl)carbonylaminomethyl]-4-(1,3-thiazol-5-yl) benzene which are useful for the treatment of proliferative, autoimmune or inflammatory diseases |
CN108601764A (zh) * | 2015-03-18 | 2018-09-28 | 阿尔维纳斯股份有限公司 | 用于靶蛋白的增强降解的化合物和方法 |
US20170037004A1 (en) * | 2015-07-13 | 2017-02-09 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
CN110072866A (zh) * | 2016-09-13 | 2019-07-30 | 密执安大学评议会 | 作为bet蛋白降解剂的稠合的1,4-二氮杂* |
Non-Patent Citations (1)
Title |
---|
黄英男;吴昊;沈锡中;: "乙型肝炎肝硬化抗病毒治疗研究进展", 复旦学报(医学版), no. 02, 15 March 2013 (2013-03-15), pages 233 - 238 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116554174A (zh) * | 2021-01-22 | 2023-08-08 | 泰比棣医药科技(石家庄)有限公司 | 一种降解脱氧核糖核酸(dna)聚合酶的化合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2022156764A1 (zh) | 2022-07-28 |
CN116802180B (zh) | 2024-05-28 |
CN116554174A (zh) | 2023-08-08 |
ZA202307894B (en) | 2024-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116802180B (zh) | 一种降解脱氧核糖核酸(dna)聚合酶的化合物及其用途 | |
KR102182663B1 (ko) | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 | |
BR112021008449A2 (pt) | Métodos para entregar um ácido nucleico a uma célula, para entregar um ácido nucleico ao citosol de uma célula, composição, para tratar uma doença, para entregar um sirna ao fígado de um animal e para tratar uma infecção viral por hepatite b em um animal, kits, polímero desestabilizador de membrana, conjugados de ácido nucleico de fórmula (x), uso de um conjugado e composição farmacêutica | |
US20050009775A1 (en) | Nucleoside compounds in hcv | |
BR112013016761B1 (pt) | Uso de um composto, composto e composição farmacêutica | |
TW309512B (zh) | ||
CN104903334A (zh) | 一种替诺福韦前药及其在医药上的应用 | |
EP1218544A1 (en) | Methods for identifying rna binding compounds | |
AU2018271643B2 (en) | Hepatitis B virus surface antigen inhibitor | |
JP2018087243A (ja) | ワクチンアジュバントおよび治療剤としての短鎖オリゴヌクレオチドの設計 | |
US6995146B2 (en) | Compositions and methods for treatment of hepatitis C virus-associated diseases | |
CN113613661A (zh) | 用于抑制HIF-2α(EPAS1)的表达的RNAi试剂、其组合物和使用方法 | |
CN115397471A (zh) | 包括核酸和半衰期延长基序的化合物 | |
TWI832678B (zh) | 半胱氨酸蛋白酶抑制劑及其用途 | |
Zhang et al. | Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme | |
BR112020021949A2 (pt) | ligantes dirigidos à integrina e seus usos | |
US8350042B2 (en) | Antiviral compounds for the treatment of HCV infection | |
WO2014025749A2 (en) | Small molecule inhibitors of viral protein interactions with human t-rna | |
JP2007506788A (ja) | Hcv感染阻害剤とその使用法 | |
CN112679489B (zh) | N-磺酰基杂环衍生物及其制药用途 | |
EP4176875A1 (en) | Pharmaceutical composition, its use as a drug and new compounds, especially for treating sars-cov-2 infection | |
CN117535287A (zh) | 乙型肝炎病毒基因的小干扰核酸及其用途 | |
TW202344687A (zh) | 靶向血管緊張素原的siRNA及其醫藥用途 | |
TW202400788A (zh) | 用於靶向遞送治療劑的雙環雜環及其配體 | |
TW202340465A (zh) | 靶向lpa的sirna及綴合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |